amifostine for nasoduodenal delivery (XER-001)
/ Xerient Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 12, 2026
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
(clinicaltrials.gov)
- P1/2 | N=36 | Recruiting | Sponsor: Xerient Pharma | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1